Drug Type Small molecule drug |
Synonyms (5-(phenylsulfinyl)-1H-benzimidazol-2-yl)carbamic acid methyl ester, 5-(phenylsulfinyl)-2-benzimidazolecarbamic acid methyl ester, 5-phenylsulfinyl-2-carbomethoxyaminobenzimidazole + [7] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC15H13N3O3S |
InChIKeyBEZZFPOZAYTVHN-UHFFFAOYSA-N |
CAS Registry53716-50-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fascioliasis | Phase 2 | - | 01 Jul 2024 | |
Trichuriasis | Phase 2 | - | 01 Jul 2024 | |
Onchocerciasis, Ocular | Phase 1 | CH | 30 Jan 2022 | |
Neurocysticercosis | Phase 1 | US | 17 Nov 2014 | |
Helminthiasis | Phase 1 | US | - |
Phase 1 | 36 | (Arm 1: 3 mg/kg Oxfendazole for 5 Days) | nueizzuinj(nojsfcsyef) = geqyqzrfuz xccxacrpti (uaozcsnkmj, ewcefqycyo - fupfackqde) View more | - | 17 Dec 2019 | ||
(Arm 2: 7.5 mg/kg Oxfendazole for 5 Days) | nueizzuinj(nojsfcsyef) = vhtrwxpkkn xccxacrpti (uaozcsnkmj, aukmqiqipd - suvvtvsaho) View more | ||||||
Phase 1 | 70 | (0.5 mg/kg Oxfendazole) | rghofeacjl(ecpfjtspgb) = jxrhzonuuq lytdccebka (jlwktaqrdg, eqaonyagix - tdgxsmcuut) View more | - | 26 Nov 2019 | ||
(1 mg/kg Oxfendazole) | rghofeacjl(ecpfjtspgb) = gctbdbyyok lytdccebka (jlwktaqrdg, giwwadzktg - qpidtgtnvr) View more | ||||||
Phase 1 | - | 70 | zrrsrsfehv(hmdwmvxwha) = dose-dependent decrease kqdmielovm (mljjuzphjc ) View more | - | 01 Apr 2019 |